UK biotech industry criticizes US and EU trade negotaitions

4 March 2020
bia_logo_large

UK Bioindustry Association (BIA) chief executive Steve Bates has given a lukewarm reaction to the government’s stance towards trade negotiations with the European Union and the USA.

In recent days, the British government  set out its negotiating position for the UK’s future relationship with the EU, as well as its  approach towards trade talks with Washington.

The UK says it is seeking “the type of agreement which the EU has already concluded in recent years with Canada and other friendly countries,” which would amount to a comprehensive free trade agreement based on zero tariffs and zero quotas.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology